Document:

Argus Health Systems Participating Agreement for Individual Pharmacy

 Exhibit 10.23 
  

							
		 		 	ARGUS	  	
		 		 	 Health Systems, Inc.
  

		 		 		  	1300 WASHINGTON STREET
		 		 		  	KANSAS CITY, MISSOURI
		 		 		  	 64105-1433
  
 WWW.ARGUSHEALTH.COM

 Argus Health Systems, Inc. 
 Participating Agreement for Individual Pharmacy 
 This Participating Agreement for Individual
Pharmacy (“Agreement”) is effective as of this 23 day of February, 2007 (the “Effective Date”), by and between Argus Health Systems, Inc., a Delaware corporation with it principal place of business at 1300
Washington Street, Kansas City Missouri 64105 (“Argus”) and CDS Pharmacies, Inc., a Florida [state of domicile] Pharmacy [type of entity] with its principal place of business at 9371 Cypress Lake Drive, No. 8,
Fort Myers, Florida 33919 [address] (“Participating Pharmacy”). 
 WHEREAS, Argos has established the Integrated Pharmacy Network System (IPNS©) for the
electronic processing of prescription and certain other related claims. 
 WHEREAS, Argus maintains networks of pharmacies to provide pharmacy services.

 WHEREAS, Participating Pharmacy owns and operates one or more (but no more than four) pharmacies. 
 WHEREAS, Participating Pharmacy desires to participate in one or more pharmacy networks available through Argus, upon the terms and conditions set forth in this
Agreement. 
 In consideration of the mutual promises herein, the parties agree as follows: 
  

	1.	Definitions 

 The capitalized terms as used in this
Agreement shall have the meanings stated in the body of the Agreement or in Exhibit 1. 
  

	2.	Services Provided by Argus 

  

	 	2.1.	Administrative Services 

 When
Participating Pharmacy participates in an Argus Network, Argus shall: (a) receive Claims in Argus IPNS© Format through
IPNS© at the point-of-sale from Participating Pharmacy or such other means authorized in writing by Argus, (b) verify
on-line that a Member is Eligible, (c) process Claims, (d) report whether a Claim received through IPNS© is Paid,
Denied, Reversed or Rejected, (e) prepare and distribute Remittance Advices monthly and mail Disbursements within ten (10) days of the end of a Financial Cycle to Participating Pharmacy or applicable Pharmacy Services Administration
Organization (“PSAO”), when. Participating Pharmacy utilizes the services of a PSAO, (f) provide access through a toll-free telephone number to an Argus Help Desk (the Argos Help Desk will not provide any professional advice with
respect to the provision of pharmacy services), and (g) provide Processing Messages, including, if required by a Client, Drug Utilization Review Messages and Formulary information. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	1	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

	 	2.2.	Member Identification Cards 

 Argus, Client, or a
designee of Argus or Client may furnish each Member with an Identification Card to be presented by Member to Participating Pharmacy. 
  

	 	3.	Participation in Network Plans 

 Unless
Participating Pharmacy obtains the services of a PSAO, Participating Pharmacy shall by executing a Schedule A to this Agreement elect the Argus Network Agreements (“ANA”), designating in which Networks Participating Pharmacy shall
participate. If Participating Pharmacy obtains the services of a PSAO, Participating Pharmacy shall identify the PSAO on such Schedule A which shall be authorized to elect ANA’s on behalf of Participating Pharmacy. If Participating Pharmacy or
its PSAO has elected to participate in an ANA, then Participating Pharmacy agrees to Disbursements at rates set forth in the ANA (as may be amended from time to time in accordance with this Agreement) and shall fill prescriptions in accordance with
the terms and conditions of this Agreement. In all events, Participating Pharmacy shall be deemed to have accepted participation and corresponding rates in any Argus Network in which Participating Pharmacy adjudicates a Claim in that network.

  

	4.	Obligations of Participating Pharmacy 

  

	 	4.1.	Verifying Eligibility and Validity of Prescription 

 Participating Pharmacy shall examine the Identification Card presented with the prescription. Participating Pharmacy shall not submit a Claim to Argus until it has preliminarily determined that the individual is Eligible and that the
prescription is valid. Participating Pharmacy will not be paid for Pharmacy Services provided to an individual whose eligibility was not correctly submitted to Argus. 
  

	 	4.2.	Submitting Claims 

 Participating Pharmacy shall submit each Claim to Argus in Argus IPNS© Format for Processing. In the event that the
Claim cannot initially be transmitted on-line, Participating Pharmacy shall make reasonable attempts to retransmit the Claim. If such retransmission fails, Participating Pharmacy shall call the Argus Help Desk through its toll-free number, as soon
as reasonably practical, to make acceptable alternative arrangements to submit the Claim on magnetic tape or on paper in Argus IPNS© Format. In no event shall Participating Pharmacy submit a Claim later than thirty (30) days after filling the prescription (or such later time period that may
be required by law); Participating Pharmacy shall not receive Disbursements for Claims submitted after such thirty (30) day period (or longer time period if required by law). Participating Pharmacy shall resubmit a Claim that is Reversed within
thirty (30) days of the date the Claim was originally submitted (or longer time period if required by law) in every instance that the prescription was not promptly delivered or completely filled. Participating Pharmacy must notify Argus in
writing of any alleged error, miscalculation, discrepancy or basis for questioning the correctness of any Claim (whether Paid, Denied, Rejected, or Reversed) within ninety (90) days after the Remittance Advice is sent. Otherwise, Participating
Pharmacy will be deemed to have 

  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	2	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

 
confirmed the accuracy of the Claims processed and/or Paid during that Financial Cycle. This does not apply with respect to any overpayments made to
Participating Pharmacy. In no event will Argus have any liability above or beyond Claim amounts during such ninety (90) day period. 
  

	 	4.3.	Communicating with the Member 

 If the Claim is
Denied or Rejected, Participating Pharmacy shall promptly inform Member. 
  

	 	4.4.	Dispensing Covered Medication 

 All Pharmacy
Services shall be rendered under the supervision of a licensed pharmacist and according to prescriber directions in accordance with applicable Law and Pharmacy Standards. Without limiting the generality of the foregoing, and subject to the
professional judgment of the pharmacist, in providing Pharmacy Services, Participating Pharmacy shall (i) provide appropriate prescription drug product consultation and counseling as required by Law and Pharmacy Standards, (ii) obtain and
respond to all Processing Messages, including all DUR Messages and Formulary information, and (iii) dispense Covered Medications to each Member only in accordance with Law, Pharmacy Standards, and the design and Formulary of the applicable
Connected Plan. Participating Pharmacy and its pharmacists must exercise sound professional judgment at all times when providing Pharmacy Services to Members. Participating Pharmacy may refuse to provide Pharmacy Services to an Eligible Member based
on that professional judgment, which must be documented. 
  

	 	4.5.	Collecting Copayments 

 Participating Pharmacy
shall charge and collect from Member the lesser of (a) the Usual and Customary Charge or (b) the applicable Copayment. Unless otherwise directed in writing by Argus, in no event shall Participating Pharmacy collect any greater amount or
any other taxes, fees, surcharges or compensation from Member. Participating Pharmacy shall not discount or waive any Copayment and shall not seek to collect any Copayment from Argus or Clients. Participating Pharmacy shall not impose on Member any
charges other than the Copayment related to the dispensing of the Covered Medication. Participating Pharmacy agrees that in no event, including but not limited to, nonpayment, insolvency, or bankruptcy of Argus or breach of this Agreement, shall
Participating Pharmacy bill, charge, collect a deposit from, seek compensation, remuneration or reimbursement from, or have any recourse against a Member for the provision of Pharmacy Services related to a Covered Medication. This does not prohibit
collection of Copayment in accordance with the terms of this Agreement. Participating Pharmacy further agrees that (a) this provision shall survive the termination of this Agreement regardless of the cause giving rise to termination and shall
be construed to be for the benefit of Members, and that (b) this provision supersedes any oral or written contrary agreement now existing or hereafter entered into between Participating Pharmacy and Member. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	3	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

	 	4.6.	Generic Dispensing 

 Participating Pharmacy shall
fill prescriptions with generic medications whenever (a) permitted and in accordance with applicable Law and Pharmacy Standards; (b) available at less cost than non-generic medications; and (c) in compliance with the applicable
Formulary. 
  

	 	4.7.	Passing Sales Tax Remittances onto the Taxing Authorities 

 Participating Pharmacy shall inform Argus in Argus IPNS© Format of the proper amount of all
federal, state and local sales taxes payable with respect to any sales of Covered Medications to Member. Participating Pharmacy shall not seek to be reimbursed and shall not submit or seek to collect from Argus or Clients (a) any amounts for
taxes or charges other than sales taxes; or (b) any amounts of which Argus was not informed with the electronic submission of a Claim for Processing. Participating Pharmacy shall assume the responsibility of making and shall timely make
payments to the appropriate taxing authorities of the amount of Sales Tax Remittances received from Argus. 
  

	 	4.8.	Recordkeeping 

 For a period of three
(3) years, or such longer period as required by Law, from the date Pharmacy Services were rendered, Participating Pharmacy shall maintain all pharmacy records and data relating to the provision of Pharmacy Services to Members and its
responsibilities under this Agreement in a manner consistent with Pharmacy Standards and Law, including, without limitation, maintaining original prescriptions; daily prescription logs; wholesaler, manufacturer and distributor invoices; prescriber
information; patient profiles; and signature logs. A signature log must contain, at a minimum, the prescription number, the date the Covered Medication was delivered to Member or Member’s representative, the signature of Member or Member’s
representative to whom the prescription for a Covered Medication was delivered, and authorization for the release of the information to Argus and/or Client. 
  

	 	4.9.	Applying Administrative and Billing Practices 

 Participating Pharmacy shall not apply administrative and billing practices to Argus, Clients or Members or charge prices for products and services to Members, regardless of whether such products and services are covered by a Connected
Plan, that are less favorable than such practices applied or such prices charged to others. Participating Pharmacy agrees not to conditionally or restrictively endorse a Disbursement instrument, and Argus and Clients shall not be bound by any such
attempt or endorsement. 
  

	 	4.10.	Providing Services Fairly 

 Unless professional
judgment of the pharmacist dictates otherwise, Participating Pharmacy shall not refuse to provide Pharmacy Services to an Eligible Member under a Connected Plan or attempt to disenroll any Member. Participating Pharmacy shall not discriminate
against Members because of race, national origin, color, sex, marital status, sexual orientation, religion, medical condition, disability, political convictions, source of payment, or participation in any Plan. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	4	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

	 	4.11.	Making Covered Medications Available 

 Participating Pharmacy shall use its best efforts to maintain an adequate supply of Covered Medications. 
  

	 	4.12.	Maintaining Data Transmission Capabilities 

 Participating Pharmacy shall provide and maintain at its expense the equipment, software, and communications network transmission capabilities necessary to submit Claims in Argus IPNS© Format and to receive Processing Messages, including DUR Messages and Formulary information. 
  

	 	4.13.	Participating in Managed Care and Other Client Initiatives 

 Participating Pharmacy shall participate in any initiative developed by Argus or Clients, which initiatives may include without limitation programs for drug utilization review (DUR), Formulary management, generic substitution management,
disease management, and Utilization Management. 
  

	 	4.14.	Payment of Argus Charges and Claim Overpayments 

 Participating Pharmacy agrees that it shall owe Argus the charges set forth in Exhibit 3 hereto and any overpayments made to Participating Pharmacy for Claims or otherwise. In addition, Participating Pharmacy acknowledges and agrees that to
the extent Argus and or Client incur penalties that result from Participating Pharmacy’s actions, inactions, or other failure to comply with this Agreement and/or applicable Law, Participating Pharmacy shall immediately owe and pay any such
penalties imposed upon Argos and/or Client, other charges. Participating Pharmacy acknowledges that Argus may deduct the amount of such charges, overpayments, and penalties from Disbursements or other remittances to Participating Pharmacy. In the
event no such deduction is made, Participating Pharmacy shall pay such charges, overpayments, and/or penalties to Argus within thirty (30) days of the receipt of an invoice therefor. Participating Pharmacy shall pay late fees at the rate of the
lesser of one and one-half percent per month or the highest percent allowed by Law from the payment due date until the invoice is paid in full. Argus may deduct unpaid charges, overpayments, penalties and/or late fees from future Disbursements or
remittances. Participating Pharmacy shall reimburse Argus for its reasonable expenses, including attorneys’ fees and costs, in enforcing this Agreement, including this Section 4.14. Argus may use a lockbox arrangement in accepting payment
from Participating Pharmacy. Participating Pharmacy therefore agrees not to attempt to affect an accord or satisfaction through a payment instrument or accompanying written communication and not to conditionally or restrictively endorse a payment
instrument, and Argus shall not be bound by any such attempt or endorsement. 
  

	 	4.15.	Rebates 

 Argus and/or Clients have the right to
submit all Claims for Covered Medications for Eligible Members to pharmaceutical companies in connection with rebate or other similar programs. Participating Pharmacy shall not submit any of the Claims for Covered Medications for Eligible Members to
any pharmaceutical company for the purpose of receiving any rebates, discounts, or the like, except as authorized by Argus in advance in writing. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	5	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

	5.	Additional Representations and Responsibilities of Participating Pharmacy 

  

	 	5.1.	Communication and Procedures 

 Participating
Pharmacy shall develop, implement and maintain efficient and accurate procedures for administering its responsibilities hereunder and shall communicate openly with Argus and Clients with respect thereto. 
  

	 	5.2.	Accreditation and Licensure 

 Participating
Pharmacy represents and warrants that Participating Pharmacy and each on-staff pharmacist is in and shall maintain good standing with all federal, state, and local regulatory bodies and has and shall maintain the licenses and certifications required
by Law to provide Pharmacy Services to Members. Participating Pharmacy shall provide evidence of such good standing, certification and licensure at no charge to Argus, a Client or a designee of either Argus or Client within ten (10) days of
written request by any of them. If Participating Pharmacy is sanctioned by the Office of Inspector General (OIG) and is not eligible to participate in Medicare, Medicaid, or other Federal health care programs, Participating Pharmacy is not eligible
to participate in any Argus network. Participating Pharmacy shall notify Argus in writing within ten (10) days of the suspension, revocation, limitation, restriction, or any other disciplinary action implemented by the OIG or any regulatory
body having jurisdiction over Participating Pharmacy and its pharmacists. 
  

	 	5.3.	Professional Liability Insurance 

 Participating Pharmacy represents and warrants that it maintains, and agrees that it shall maintain in full force and effect throughout the term of this Agreement, minimum primary professional liability insurance in amounts of no less than
$1,000,000 per claim and $3,000,000 in the aggregate of all claims per 12-month period or such greater amount required by Law or Pharmacy Standards. When allowed by Law, these coverage amounts may be obtained through excess professional liability
insurance other than an umbrella policy providing excess limits over more than one line of coverage. Promptly upon Argus’
 written request, Participating Pharmacy shall provide Argus written evidence confirming this insurance is in effect. Participating Pharmacy shall notify Argus in writing not less than thirty
(30) days in advance prior to any cancellation, non-renewal, or material change in this coverage. Participating Pharmacy must notify Argus immediately in writing if its insurance is canceled, lapsed, or otherwise terminated. 
  

	 	5.4.	Audits of Pharmacy Records 

 Argus, Clients, and/or third parties designated by Argus or Clients shall have the right, for the term of this Agreement and for three (3) years thereafter, upon ten (10) days prior notice to Participating Pharmacy, or such lesser
or greater time as is required or allowed by Law, to review, audit, examine, and reproduce any of the Participating Pharmacy’s books, records, prescription files, and signature logs pertaining to Covered Medications for Eligible Members and/or
Participating Pharmacy’s compliance with this Agreement. In addition,
Participating Pharmacy shall provide records or copies of records requested by Argus, Clients, or their third party designees within ten (10) days from the date of a written request for such records. Participating Pharmacy shall cooperate in
good faith in such audits. If it is determined 

  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	6	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

 
that Disbursements have resulted in overpayments to a Participating Pharmacy, any such overpayments shall become immediately due and owing. Argus may deduct
any such overpayments from any Disbursements or remittances as set forth in Section 4.14 above. 
  

	 	5.5.	Delegation to PSAO To Bind And Represent Participating Pharmacy 

 If Participating Pharmacy belongs to an affiliated group of pharmacies that obtain the administrative services of a PSAO, it has so
indicated on Schedule A hereto. Participating Pharmacy represents and warrants that it has authorized, and for the term of this Agreement and any renewals thereof shall continue to authorize, its PSAO to bind the Participating Pharmacy, individually
and as part of an affiliated group of pharmacies, to all the terms and conditions of an ANA. Participating Pharmacy shall promptly provide to Argus upon Argus’ written request evidence of PSAO’s authority to bind the Participating Pharmacy. 
  

	 	5.6.	Participating Pharmacy Information 

 Participating Pharmacy shall electronically provide Argus, in the format Argus requests, information about its availability to Members, including without limitation information pertaining to its locations and operating hours. Participating
Pharmacy shall provide thirty (30) days’ prior written notice to Argus on
an Argus-provided form of changes in the location, significant changes in the operating hours, closing, or change of ownership (including without limitation the purchase or sale) of Participating Pharmacy. Participating Pharmacy acknowledges the
need to provide accurate and thorough information so Argus can convey accurate access and density information to Clients. 
  

	 	5.7.	Regulatory Addendum and Compliance with Law 

 Participating Pharmacy acknowledges that various federal and state mandates may apply with respect to this Agreement and the Pharmacy Services provided to Members of Argus’ Clients. Participating Pharmacy represents and warrants that it is, and shall remain, in compliance with all
applicable Laws, including but not limited to those Laws referenced in the Regulatory Addendums attached hereto and incorporated herein by this reference. 
  

	6.	Information Obtained Through DUR Messages 

 Participating Pharmacy acknowledges and agrees that (a) information contained in DUR Messages is derived from third party sources and is not independently developed by Argus, and Argus utilizes industry materials
and the advice and resources of outside vendors and healthcare professionals to provide DUR Messages, (b) the usefulness of DUR Messages and Formulary information is necessarily limited by the amount of patient input into the IPNS©’ database as a result of Claims processing, the amount of information provided by Clients, and the thoroughness and
accuracy of industry information and information provided by third parties, (c) DUR Messages and Formulary information are intended as an aid to, and not a substitute for, the knowledge, expertise, skill and judgment of prescribers,
Participating Pharmacy, on-staff pharmacists, or other healthcare professionals, (d) Participating Pharmacy, prescribers, on-staff pharmacists, other healthcare professionals, and Clients are individually responsible for acting or not acting
upon information generated and transmitted by Argus including without limitation upon DUR Messages or Formulary information, (e) Argus does not control the healthcare decisions made or actions 

  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	7	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

 
taken by Participating Pharmacy, prescribers, on-staff pharmacists, other healthcare professionals, Clients or Members, (f) the DUR Messages and
Formulary information do not contain all currently available information on healthcare or pharmaceutical practices, (g) Argus is not responsible for failing to include information in a DUR Message or in Formulary detail that is not specifically
requested by Clients, for the actions or omissions of contributors of information to Argus, or for misstatements or inaccuracies in industry materials utilized by Argus, and (h) all warranty disclaimers and exclusions made by contributors of
information or data to Argus shall apply to the Argus services provided hereunder. 
  

	7.	Term and Termination 

  

	 	7.1.	Term of Agreement 

 Unless otherwise terminated
pursuant to this Section 7, this Agreement shall commence on. the Effective Date, the initial term shall continue for a term of five (5) years from the Effective Date, and unless terminated as provided by this Section 7, the Agreement
shall automatically renew for successive one-year renewal terms; provided, however, that this Agreement shall terminate upon written notice no less than one hundred and eighty (180) days prior to the end of the initial term or any renewal term.

  

	 	7.2.	Termination upon Insolvency 

 Either party may
terminate this Agreement with written notice to the other immediately upon the filing by or against the non-terminating party of any action under the Federal Bankruptcy Act, or any other law or act regarding insolvency, reorganization, arrangement,
or extension for the relief of debtors, including the assignment of assets for the benefit of creditors, and the appointment of a receiver or trustee for transfer or sale of a material portion of the non-terminating party’s assets. 

 

	 	7.3.	Termination for Default 

 If there is any material
default by either party in the performance of the terms and conditions of this Agreement, the non-defaulting party may terminate this Agreement upon sixty (60) days’ prior written notice, provided, however, that the defaulting party has
not cured such default within ten (10) days prior to the end of such sixty (60) day period. 
  

	 	7.4.	Immediate Termination 

 Argus
may terminate this Agreement immediately upon written notice to Participating Pharmacy in the event of (i) Participating Pharmacy’s breach of the representations and warranties set forth in Section 5 hereof; (ii) the occurrence
of any of the events described in submission of incorrect or false Claim information. Further, Argus may terminate Participating Pharmacy from participating in any specific Connected Plan’s network without cause upon a 30-day written notice to Participating Pharmacy (or such longer period as required by applicable
law). Participating Pharmacy acknowledges and agrees that Connected Plans may not utilize all pharmacies in a network for their respective Plan Networks. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	8	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

	 	7.5.	Rights and Remedies in the Event of Termination or Breach 

 In the event of termination of this Agreement for any reason, in addition to all other rights and remedies Argus may have at law, equity, or under this Agreement, Argus shall have the right to deduct from any amounts owing to Participating
Pharmacy any amounts which Participating Pharmacy owes to Argus. 
 In the event Participating Pharmacy breaches any provision of the
Agreement, in addition to all other termination rights, Argus shall have the right to (i) suspend any and all obligations of Argus under and in connection with this Agreement, (ii) impose reasonable investigation and handling fees, and/or
(iii) offset against any amounts owed to Participating Pharmacy under this Agreement or under any other agreement between Argus and Participating Pharmacy, any amounts required to be paid by Participating Pharmacy to Argus. These rights and
remedies are in addition to any and all other rights and remedies that may be available to Argus under the Agreement or at law or equity. 
  

	 	7.6.	Survival of Certain Provisions 

 Notwithstanding
the termination of this Agreement, Sections 4.5, 4.8, 4.14, 4.15, 5.4, 9, 10, 11, and any obligations that arise prior to termination of the Agreement shall survive such termination. 
  

	8.	Performance Warranty 

 In the event of any claim by
Participating Pharmacy that Argus has not performed its obligations to provide services as required by this Agreement, the sole obligation of Argus shall be to re-process the Claim or re-perform any service which does not conform to this Agreement
at Argus’ expense, provided that such failure to perform is not due to an act or omission by Participating Pharmacy. 
 EXCEPT AS
PROVIDED IN THIS SECTION 8, NOTWITHSTANDING ANY OTHER TERM OF THIS AGREEMENT, NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, ARE MADE BY ARGUS WITH
RESPECT TO ANY GOODS SOLD OR SERVICES PROVIDED HEREUNDER. 
  

	9.	Liability and Indemnification 

 Argus shall not be
responsible to make Disbursements for Claims not submitted in accordance with this Agreement, and in particular Section 4.2 hereof, or for Claims that are Denied, Rejected, or Reversed. Participating Pharmacy shall indemnify Argus, its Clients,
and their respective shareholders, officers, directors, employees and agents, and the successors, representatives and assigns thereof, for, and hold them harmless from and against, any and all liability, loss, damage, settlement, claim, injury,
demand, judgment, and expense, including attorneys lees, arising directly or indirectly from (a) Argus’ response to subpoenas or other requests for Participating Pharmacy information, (b) failure of Participating Pharmacy to act in
accordance with Pharmacy Standards or Law, (c) any actual or alleged malpractice, negligence, misconduct, act or responsibility of Participating Pharmacy, or (d) the provision of Pharmacy Services or the sale, compounding, dispensing,
manufacturing, or use of a drug or device dispensed by Participating Pharmacy. All liability arising from the provision of Pharmacy Services by Participating Pharmacy shall be the sole responsibility of Participating Pharmacy. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	9	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

 In the event Participating Pharmacy utilizes the services of a PSAO, Participating Pharmacy shall
indemnify Argus, its Clients and their respective shareholders, officers, directors, employees and agents, and the successors, representatives and assigns thereof, for, and hold them harmless from and against, any and all liability, loss, damage,
settlement, claim, injury, demand, judgment, and expense, including attorneys fees, arising directly or indirectly from (a) failure of Participating Pharmacy to act in accordance with its agreement with PSAO, and (b) any dispute between
Participating Pharmacy and PSAO. 
 NOTWITHSTANDING ANY OTHER ‘PERM OF THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL (INCLUDING BUT NOT LIMITED TO LOSS OF PROFITS) OR PUNITIVE DAMAGES ARISING FROM THE RELATIONSHIP OF THE PARTIES OR THE CONDUCT OF BUSINESS UNDER THIS AGREEMENT (EVEN IF THE
OTHER PARTY HAS BEEN ADVISED OF OR HAS FORESEEN THE POSSIBILITY OF SUCH DAMAGES). 
  

	10.	Confidentiality 

 For purposes of this
Section 10 and of Section 11 Proprietary Information shall include this Agreement, its terms and all information disclosed by each party to the other pursuant to negotiations between the parties. When used with respect to Argus in Sections
10 and 11, Proprietary Information shall mean: (a) all information pertaining to Argus’ business and services, (b) Argus databases, software, layouts, designs, formats, procedures in any form of expression, processes, tags,
applications, systems, and technology, (c) files, compilations, analyses, publications, edits, protocols, documents and reports, both internal and available to Participating Pharmacy and others, and (d) information pertaining to Connected
Plans, Clients, Plan Specifications, Formularies, and the identity of Members. When used with respect to Participating Pharmacy in such Sections, Proprietary Information shall mean all information pertaining to specific Pharmacy Services rendered to
individual Members. The term “Proprietary Information” as used in this Section does not include information which (1) has been or may in the future be published or is now or may in the future be otherwise in the public domain through
no fault of the receiving party; (2) prior to disclosure pursuant to this Agreement, or during negotiations therefor, is property within the legitimate possession of the receiving party; (3) subsequent to disclosure pursuant to this
Agreement is lawfully received from a third party having rights in the information without restriction of the third party’s right to disseminate the information and without notice of any restriction against its further disclosure; (4) is
independently developed by the receiving party through its agents who have not had access to such Proprietary Information; or (5) is obligated to be produced under order of a court of competent jurisdiction or other similar requirement of a
governmental agency. 
 Each party represents and warrants that it has the right to disclose its Proprietary Information
to the other party. Each party acknowledges and agrees that the other party’s
Proprietary Information constitutes confidential material and trade secrets of the other party and agrees to hold such Proprietary Information in confidence, to use and reproduce such Proprietary Information only to accomplish the intent of this
Agreement, and to use reasonable care to avoid unauthorized disclosure or use of the Proprietary Information; provided, however, that Argus is authorized to disclose this Agreement and Participating Pharmacy Proprietary Information to Clients.

  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	10	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

 All Proprietary Information, unless otherwise agreed in writing, remains the
exclusive property of the disclosing party. For purposes of this Agreement, the existence of a copyright notice or claim shall not cause or be construed to cause any part of the Proprietary Information to be published in the public domain.
Proprietary Information of Argus, including all copies in tangible form of such information, must be returned to Argus or destroyed (and certified by an officer of Participating Pharmacy as destroyed) after Participating Pharmacy’s need for it has expired or upon request of Argus, and, in any event, upon expiration or
termination of this Agreement. 
 The parties agree that monetary damages will be difficult to ascertain in the event of any breach of this
Section 10 or Section 11 below and that monetary damages alone would not suffice to compensate a party for such breach. The parties agree that in the event of violation of this Section 10 or Section 11 below, without limiting any
other rights and remedies, an injunction may be brought against any party who has breached or threatened to breach this Section 10 or Section 11, without the requirement to post bond. 
  

	11.	Ownership of Intellectual Property 

  

	 	11.1.	Ownership 

 Argus and
Participating Pharmacy shall retain full and exclusive ownership and all rights over their respective Proprietary Information, and over their respective publications, trade secrets, copyrights, trademarks and patents. Participating Pharmacy shall
not reverse engineer, decompile or disassemble or otherwise attempt to create or derive the source code of any Argus software or system. Participating Pharmacy acknowledges that Argus’ software, systems, products, services and related
documentation may contain trade secrets of Argus or third parties and may be patented or copyrighted. Participating Pharmacy agrees not to use, reproduce, adapt, or distribute any originals or copies of the foregoing, in whole or in part, without
Argus’ advance written consent, and agrees that any such copies shall bear the
same proprietary legends or notices as appear in this Agreement and on the originals. 
  

	 	11.2.	Advertisement 

 Neither
Participating Pharmacy nor Argus may advertise or use any trademarks, service marks, or symbols of the other party without first receiving the prior written consent of the party owning the mark and/or symbol with the following exceptions: Argus and
Clients may use the name and addresses of Participating Pharmacy in informational brochures or other publications provided to Members or potential Members or that Argus provides to Clients or potential Clients. Participating Pharmacy may use Clients
’ names for the sole purpose of informing Members and the general public that
Participating Pharmacy participates in a Network. Upon termination of this Agreement, Participating Pharmacy shall immediately discontinue the use of any name, symbol, trademark, or service mark of Argus in advertising and/or any other promotional
information. 
  

	12.	Miscellaneous 

  

	 	12.1.	Relationships 

 The parties hereto are independent
contracting parties, and nothing in this Agreement is All of the information on this page constitutes a trade secret, privileged or confidential information, as such are interpreted under the Freedom of Information Act and applicable case law
employer/employee relationship, a partnership, a joint venture relationship, an agency relationship, or any other legal relationship between the parties other than or in addition to that of independent contracting parties. Neither party will act as
or be deemed a representative of the other party. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	11	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

	 	12.2.	Assignment 

 Neither party may assign this
Agreement without the prior written consent of the other party, which consent may not be unreasonably withheld; provided, however, that Argus may, without consent, assign this Agreement to any direct or indirect parent, subsidiary, or affiliated
company or to a successor company. Any permitted assignee shall assume all obligations of its assignor under this Agreement. This Agreement shall inure to the benefit of and be binding upon each party, its respective successors and permitted
assignees. 
  

	 	12.3.	Force Majeure 

 Any party’s delay in, or
failure of, performance under this Agreement shall be excused where such delay or failure is the result of causes that are beyond the affected party’s reasonable control, including acts of nature, fire, or other catastrophe, electrical,
computer, software, transmission, communications or mechanical failure, work stoppage, delays or failure to act of any carrier or agent, direction or effect of an order from a court or government agency or body, or any other cause beyond a
party’s direct control. 
  

	 	12.4.	Notices 

 Any notice required to be given pursuant
to the terms and provisions of this Agreement shall be in writing, postage prepaid, and shall be sent by certified or registered mail, return receipt requested, or by facsimile, to Argus or Participating Pharmacy at the address set forth at the
beginning of this Agreement or at such address as may subsequently be provided in writing to the respective parties. The notice shall be addressed and made to the President of the party to which notice is being sent. 
  

	 	12.5.	Entire Agreement 

 This Agreement, together with
its exhibits, schedules, ANAs, Regulatory Addendums, and Plan requirements communicated to Participating Pharmacy (all of which are incorporated herein by this reference as if fully set forth herein), contains the entire Agreement between
Participating Pharmacy and Argus relating to the subject matter hereof. This Agreement, the exhibits, schedules, ANAs, Regulatory Addendums, and Plan requirements communicated to Participating Pharmacy are referred to collectively herein as the
“Agreement”. In the event of any conflict between these documents, the applicable Regulatory Addendum controls. Any prior agreements, promises, negotiations or representations, either oral or written, relating to the subject matter of this
Agreement, not expressly set forth herein, are of no force or effect. From time to time, Argus may amend the Agreement (including any exhibits, schedules, ANAs, Regulatory Addendums, or Plan requirements) by giving thirty (30) days advance
written notice to Participating Pharmacy of the terms of the amendment. If Participating Pharmacy continues to submit claims after the effective date of any amendment, Participating Pharmacy will be deemed to have accepted such amendment as if it
had given its express written consent thereto. Invalidity of any term or portion of the Agreement shall not affect the validity, effectiveness, or enforceability of any other provision. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	12	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

	 	12.6.	Heading 

 The headings or articles and sections
contained in this Agreement are for reference purposes only, and do not affect in any way the meaning or interpretation of this Agreement. 
  

	 	12.7.	Governing Law and Venue 

 This Agreement shall be
construed and enforced in accordance with the laws of the State of Missouri, without regard to conflict of law principles. The venue and jurisdiction for any action arising under this Agreement will be in the state or federal courts in Missouri. The
parties consent to the jurisdiction and venue of the state or federal courts in Missouri and waive any objections to such jurisdiction and venue. 
  

	 	12.8.	Third Party Beneficiaries 

 Except for the
indemnification provision, this Agreement is intended solely for the benefit of the parties, and in no event shall any third party, including without limitation any prescriber, Member, governmental entity, PSAO, or contractor of PSAO or
Participating Pharmacy, have any rights or cause of action under or right to enforce the terms of this Agreement. 
  

	 	12.9.	Waiver 

 Failure to exercise any of the rights
granted under this Agreement for any one default shall not be a waiver of the right to exercise any of these rights for subsequent defaults. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	13	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

 Pharmacy is not authorized to add, delete or make any modifications to this Addendum (whether typed, hand-written, or
otherwise) without the prior written consent of Argus. Any such modifications to this Addendum without the written authorization of Argus shall be invalid and shall have no effect. By signing below, the undersigned represents and warrants that
it has received and executed the Participating Agreement. The undersigned understands and agrees that all the terms and conditions established in the Participating Agreement, except to the extent inconsistent with the terms and conditions of this
Addendum, shall apply to this Addendum. Participating Pharmacy and Argus have caused this Addendum to be executed by their respective officers or representatives duly authorized to do so. Participating Pharmacy shall become a participant in this
network effective as set forth above. Any prior agreements, promises, negotiations, or representations concerning the subject matter covered by this Addendum are of no force and effect. 
 IN WITNESS WHEREOF, Participating Pharmacy and Argus have executed this Agreement by their representatives duly authorized as of the date first written above. 
  

									
	Participating Pharmacy:	 		 		 	Argus Health Systems, Inc:
				
	 /s/    Paul D. Hamilton
	 		 		 	 /s/    Patricia Yakimo

	Name (Signature)	 		 		 	Name (Signature)
				
	 Paul D. Hamilton
	 		 		 	 Patricia Yakimo

	Name (Printed)	 		 		 	Name (Printed)
				
	 O.P. Managing Pharmacist
	 		 		 	 Senior V.P.

	Title	 		 		 	Title
				
	 2/23/07
	 		 		 	 4/23/07

	Date	 		 		 	Date
					
	 CDS Pharmacies, Inc.
	 		 		 		 	
	Legal Name of Participating Pharmacy	 		 		 		 	

  

									
	County	 		 		 		 	
	Code	 	 071
	 		 	Telephone:	 	(800) 522-7487
	NCPDP#:	 	 1024380
	 		 		 	
	NPI #:	 	 1215 073820
	 		 		 	
	Telephone:	 	 239-415-3309
	 		 		 	
	Fax:	 	 239-433-5518
	 		 	Fax:	 	(816) 435-7440

  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	14	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

					
		 	ARGUS	  	
		 	 Health Systems, Inc.
  

		 		  	1300 WASHINGTON STREET
		 		  	KANSAS CITY, MISSOURI
		 		  	64105-1433
			
		 		  	WWW.ARGUSHEALTH.COM

 Schedule A 
 Argus Network Agreements 
  ̈ [Check this box only if Participating Pharmacy obtains the services of a
pharmacy services administration organization. (“PSAO”) which is authorized to select Networks for Participating Pharmacy.] Participating Pharmacy obtains the administrative services of a PSAO. Participating Pharmacy’s PSAO is
                     [name]
                     [address]. Pursuant to Section 5.5 of this Agreement, Participating Pharmacy’s PSAO is hereby authorized to
select and shall select the Argus Network Agreements in which Participating Pharmacy shall participate unless and until otherwise notified in writing. 
 DO NOT COMPLETE THE REMAINDER OF THIS SCHEDULE IF A PSAO IS
INDICATED ABOVE. 
 Participating Pharmacy shall participate pursuant to the Agreement in all of the Argus
Network Agreements for which an election is indicated. 
 Participating Pharmacy may elect to participate in additional Networks. During the term of this
Agreement and any renewal hereof, Participating Pharmacy may elect to discontinue participation in an elected Network only by written notice on an Argus-provided form no less than six months prior to the Network participation termination date
designated on the notice. 
 Participating Pharmacy acknowledges and agrees that any Client of Argus, whether current or prospective, may, at any time
without notice from Argus or Clients to Participating Pharmacy, connect Plans to and remove Plans from any Network. 
 Certain
capitalized terms used in this Schedule are defined in Exhibit 1. For the selected network schedule to apply, Argus must receive Claims in Argus IPNS© Format at point of sale for Participating Pharmacy. 
 Participating
Pharmacy must collect at the point-of-service from Eligible Members any administrative, transaction, access or other types of such fees, when applicable. The total amount to collect from the Eligible Member will be communicated through the claims
system and may be debited from any amounts owing to Participating Pharmacy, including Participating Pharmacy’s claims payment account. 
  

					
	Copyright 2004 by Argus Health Systems, Inc.	  	15	  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law. 

					
		 	ARGUS	  	
		 	 Health Systems, Inc.
  

		 		  	1300 WASHINGTON STREET
		 		  	KANSAS CITY, MISSOURI
		 		  	64105-1433
			
		 		  	WWW.ARGUSHEALTH.COM

 ADDENDUM TO ARGUS HEALTH SYSTEMS, INC. 
 PARTICIPATING AGREEMENT 
 FOR PHARMACY
NETWORK SERVICES 
 This Addendum, by and between Argus Health Systems, inc. (“Argus”) and the undersigned pharmacy, chain,
or PSAO (“Participating Pharmacy”). is effective as of the date below,
when signed and executed by both parties. 
 Whereas, Argus and Participating Pharmacy have entered into that certain Participating Agreement, under which
Argus maintains networks of pharmacies in which Participating Pharmacy participates and provides Pharmacy Services (the “Agreement”); and 
 Whereas, Argus and Participating Pharmacy desire to amend the Agreement as set forth in this Addendum. 
 Now, therefore, Argus and Participating
Pharmacy agree as follows: 
 Participating Pharmacy acknowledges that various state and federal mandates may apply with respect to the Agreement and the
Pharmacy Services provided to Members of Argus’ clients. Participating Pharmacy represents and warrants that it is, and shall remain, in compliance with all applicable Laws, including but not limited to those Laws referenced in the Regulatory
Addendum attached hereto and incorporated herein by this reference. 
 This Addendum, including the Regulatory Addendum, and the Agreement, together with its
exhibits, schedules, and ANAs, all of which are incorporated herein by this reference as if fully set forth herein, contain the entire Agreement between Participating Pharmacy and Argils relating to the subject matter hereof. This Addendum, the
Regulatory Addendum, and the Agreement, the exhibits, schedules, and ANAs are referred to collectively as the “Agreement”. In the event of any conflict between these documents, the applicable Regulatory Addendum controls. Except as
specifically amended hereby, all provisions of the Agreement shall remain in full force and effect. Except as expressly provided herein, all capitalized terms used in this Addendum shall have the meanings set forth in the Agreement. From time to
time, Argus may amend the Agreement (including any Regulatory Addendum, exhibits, schedules, or ANAs) by giving thirty (30) days advance written notice to Participating Pharmacy of the terms of the amendment. Invalidity of any term or portion
of the Agreement shall not affect the validity, effectiveness, or enforceability of any other provision. 
 No alterations to this Addendum shall be binding
on either party unless initialed by duly authorized representatives of both parties. Participating Pharmacy and Argus have caused this Addendum to be executed by their respective officers or representatives duly authorized to do so. 
  

							
	Participating Pharmacy Name:         CDS Pharmacies, Inc.	    	Argus Health Systems, Inc.
		
	 /s/    Paul D. Hamilton                               
     2/3/07
	    	 /s/    Patricia
Yakimo                4/23/07

	Name (Signature)	    	Date	    	Name (Signature)	  	  Date
				
	 Paul D. Hamilton, Vice President, R. Ph.
	    		    	 Patricia Yakimo, SR VP
	  	
	Name and Title (Printed)	    		    	Name and Title (Printed)
		
	NCPDP #: 1024380	    	Telephone: (800) 522-7487
	NPI #: 1215073820	    		  	
		
	Address: 9371 Cypress Lake Drive #8	    	Fax: (816) 435-7440
	    Ft. Myers, Florida 33919	    		    		  	
				
	Telephone: 239-415-3309	    	Fax: 239-433-5518	    		  	
		    		    		  	

  

					
	Copyright 2004 by Argus Health Systems, Inc.	  		  	Confidential and Proprietary

 All of the information on this page constitutes a trade secret, privileged or confidential information, as such
are interpreted under the Freedom of Information Act and applicable case law.Bayer Healthcare Diabetes Care

 Exhibit 10.24 
  

			
	Certified Diabetic Services	  	 January 23, 2009

  
 BAYER HEALTHCARE
LLC, DIABETES CARE 
 DISTRIBUTOR MEDICAL BENEFIT 
 PATIENT TESTING COMPLIANCE PROGRAM AGREEMENT 
 CONTRACT MY 

 This Distributor Medical Benefit Patient Testing Compliance Program Agreement - Contract MY (“Agreement”) is made by and between Bayer
HealthCare, LLC, Diabetes Care located at 555 White Plains Road, Tarrytown, NY, 10591 (hereinafter “Bayer”), and Certified Diabetic Services located at 10061 Amberwood Road, Fort Myers, FL 33913 (hereinafter “Distributor”).

 In consideration of the mutual promises and covenants contained herein, the parties agree as follows: 
  

	1.	Introduction 

  

	1.1	Pursuant to this Agreement, Bayer agrees to sell and Distributor agrees to purchase directly from Bayer test strips, meters, controls, and ancillary products set forth in Attachment
(A), collectively “the Bayer Products” for sale and distribution directly to patients with diabetes located in the United States, District of Columbia, and Puerto Rico (“Territory”), whose diabetes management supplies are covered
as a Medical Benefit by Medicare, Medicaid or a Qualified Participating Plan (“End-users”). Distributor shall, not directly or indirectly, sell, distribute, or otherwise make available any of the Bayer Products outside of the Territory
and/or to any person or entity, except to the End-user. 

  

	1.2	Distributor is currently an Authorized Diabetes Care Center pursuant to a separate Agreement between Bayer and Distributor (Key Operating Policy and Procedure for Diabetes Care
Center Agreement), the terms of which are incorporated herein by reference. Unless otherwise specified herein, if there is any conflict between the terms in this Agreement and the terms in the Key Operating Policy and Procedures, the terms of the
Key Operating Policies and Procedures shall control. 

  

	 	1.2.1	At the time this Agreement goes into effect, the 2007 Distributor Medical Benefit Patient Testing Compliance Program Agreement, Contract MJ, Contract Number C027091 accepted by
Bayer on February 14, 2007, will be automatically terminated. This termination is not a release of any existing obligations of the Distributor under the 2007 Distributor Medical Benefit Patient Testing Compliance Program Agreement, Contract MJ,
Contract Number C027091 and Bayer retains the right to review and audit claims for [allowances/chargebacks/credits] made under the 2007 Distributor Medical Benefit Patient Testing Compliance Program Agreement, Contract MJ, Contract Number C027091
and seek repayment for any improper claims. 

  

	 	1.2.2	Distributor may not participate in any other Contract or Agreement with Bayer regarding Bayer Test Strips and/or Meters during the term of this Agreement unless agreed to by Bayer.

  

	1.3	Distributor shall furnish at least ninety-percent (90%) of Bayer Test Strips covered under this Agreement to End Users by Home Delivery either via a Mail Mode of Delivery or
Distributor’s Own Delivery Network. Mail Mode of Delivery shall include United States Postal Service, United Parcel Service, FedEx, DHL, or other recognized commercial delivery service. Distributor’s Own Delivery Network shall include
deliveries made to End Users’ Home by Distributor’s own employees or by other private carrier that provides home delivery service. 

  

	1.4	Distributor shall be a party to agreements with the Centers for Medicare and Medicaid Services (CMS) concerning Medicare Reimbursement. As such, the Distributor agrees to accept
Medicare/Medicaid assignment, process the Medicare paperwork on behalf of the End-user and accept eighty-percent (80%) of the authorized Medicare reimbursement plus the remaining twenty-percent (20%) directly from the End-user or a
supplementary insurance provider. 

  

 Page 1 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	 	1.4.1	Distributor shall be a contracted provider with the Qualified Participating Plan concerning Medical Benefit Reimbursement. As such, the Distributor agrees to accept the contracted
Medical Benefit reimbursement, process the Medical Benefit claim paperwork on behalf of the End-user and collect any copayment or coinsurance payment that is due from the End-user. 

  

	1.5	Under the conditions of paragraph 1.7 hereof, Bayer will issue an allowance to the Distributor in accordance with paragraphs 2.2, and 2.2.1 for the allowance amount set forth on
Attachment B for sales of Bayer Products made to End-users for which Distributor conducts a Patient Testing Compliance Program, as defined in Attachment C, for all End-users. 

  

	1.6	If Distributor sells Bayer Test Strips to End-users who are members of Qualified Participating Plans, as set forth on Attachment D which is in a format acceptable to Bayer, said
Qualified Participating Plans must classify Bayer Test Strips as a Medical Benefit. Participating Plans that classify Bayer Test Strips as a Pharmacy Benefit do not qualify. Distributor does not qualify for an allowance on Bayer Test Strips sold to
members of Qualified Participating Plans with which Bayer has entered into a separate Agreement for Bayer Test Strips. Distributor does not qualify for an allowance on Bayer Test Strips sold to members of Qualified Participating Plans if Distributor
does not have a written contract with the Qualified Participating Plan designating Distributor as a provider of Medical Benefits to Qualified Participating Plan members. 

  

	 	1.6.1	Distributor does not qualify for an allowance on Bayer Test Strips sold to Medicaid beneficiaries in those states where Medicaid classifies test strips as a Pharmacy Benefit.

  

	1.7	In consideration of the allowance pricing to the Distributor by Bayer, Distributor agrees to provide in a format acceptable to Bayer, sales tracing information unique to each
End-user as defined in Attachment E. Distributor shall forward such information to Bayer on a monthly basis as set forth in paragraphs 1.8 and 2.2.1. 

  

	1.8	Bayer will provide an allowance to the Distributor only for those sales for which End-user Information is provided. Distributor will only be eligible for payment of net price if the
documentation is in a format acceptable to Bayer when End-user Information is provided and it is submitted on a monthly basis. In addition, Distributor will keep on file detailed sales tracing information, including the name of each End-user, all
End-user identifiers assigned, the End-user’s address, phone number, as well as the Bayer Products sold, date of sale, and the quantity of product sold. This information including original documentation shall be made available to Bayer during
any audit pursuant to paragraph 1.9. Distributor will be eligible for allowance pricing only for those sales for which End-user Information is provided in format acceptable to Bayer and it is submitted on a monthly basis as provided by paragraph
2.2.1. 

  

	1.9	 Distributor remains responsible for the accuracy of all End-user Information submitted to Bayer. Distributor agrees that Bayer has the right to perform random
audits of Distributor’s records including phone records, invoices and other books and records of Distributor to determine that allowances have been paid in accordance with the provisions of this Agreement including that Bayer Test Strips were
sold exclusively to End-users. Such audits will be performed by Bayer at a reasonable time and in a reasonable manner, at any time, upon 48 hours prior notice. For audits conducted at the Distributor’s site, End-users’ names, addresses,
telephone numbers, physician letters and or Medicare/Medicaid numbers will not leave the premises with an auditor or Bayer representative nor will such information be used for any other purpose other than to verify that Bayer Test Strips were sold
to End-users and that the Distributor is fully performing within the terms and conditions of this Agreement. However, the auditor or Bayer representative shall be given office and telephone access to make spot-check phone calls to verify the
aforementioned information. If the audit discloses any cases wherein allowances were issued to the Distributor for non-qualifying purchases, and/or the audit discloses any cases wherein allowances were issued to the Distributor where 

  

 Page 2 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	 	 
End-user information cannot be traced to End-user, the Distributor shall reimburse Bayer for such allowance payments within thirty (30) days of receipt
of notice from Bayer, whether or not such allowances were paid as a result of an error by Distributor. 

  

	1.10	Distributor agrees to purchase Bayer Products directly from Bayer as set forth on Attachment B. 

  

	1.11	Distributor agrees not to trade out End-users to competitors blood glucose monitoring products for the term of this Agreement unless specifically requested by the
End-user’s physician, the End-users health plan, or the End-user. This includes End-users currently using Bayer Systems prior to the commencement of this Agreement as well as End-users who begin using Bayer Systems after the commencement of
this Agreement. 

  

	1.12	Bayer Test Strips, as set forth in paragraph 1.1 can only be sold by Distributor to End-users under the conditions set forth in paragraph 1.4 and shall not be displayed on retail
shelf. 

  

	1.13	Distributor shall not advertise the prices of Bayer Test Strips. Distributor shall not advertise or promote any of the Bayer Products covered by this Agreement in a manner that may
appear to violate, or may violate, any applicable law or regulation. All advertising materials of Distributor which contain or refer to Bayer Products require Bayer’s prior written approval as set forth in Section 6.5 of this Agreement.

  

	1.14	Distributor will take all necessary steps to comply with the terms of this Agreement and any state or Federal laws or regulations, including, if necessary, obtaining permission from
End-users to participate in the Patient Testing Compliance Program as described in Attachment C, obtain from End-users’ Qualified Participating Plan written authorization to provide End-users with Patient Testing Compliance Program services as
described in Attachment C and obtaining any necessary authorization to release information to Bayer as required by this Agreement. 

  

	1.15	This Agreement is conditional upon Distributor providing Bayer an acceptable list of Qualified Participating Plans as outlined on Attachment D titled “Participating Plans
List”. The Qualified Participating Plans List can be submitted in a mutually agreeable format. If Distributor requires a Qualified Participating Plan to be added to this Agreement after the date of initial acceptance by Bayer, such requests
must be made in writing thirty (30) days prior to the beginning of the next consecutive month. Upon written approval from Bayer, the Qualified Participating Plan will then be eligible for allowances on Bayer Test Strips. It is the
Distributor’s sole responsibility to ensure that the plans listed on Attachment D meet the definition of Qualified Participating Plans. Acceptance by Bayer of a plan on Attachment D does not mean that Bayer agrees that the plan meets the
requirements of a Qualified Participating Plan. 

  

	 	1.15.1	 	For purposes of this Agreement, Qualified Participating Plans are defined as follows: 

  

	 	a.	 	Any managed care organization whose plan members do not include patients whose health care is covered, in whole or in part, by Medicare, Medicaid, any other federal or state health
insurance program, except for: 

  

	 	1.	 	Those managed care organizations located in Massachusetts, Minnesota, Missouri, Ohio, Rhode Island and Texas except such managed care organizations can be Qualified Participating
Plans if Distributor has disclosed in writing to those managed care organizations the existence of an agreement between Distributor and Bayer for discounted prices on Bayer Test Strips for their plan members. 

  

 Page 3 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	 	b.	 	Any managed care plan whose plan members include patients whose health care is covered, in whole or in part, by Medicare, Medicaid or any other federal or state health insurance
program, provided that the managed care organization is: 

  

	 	1.	 	An HMO or CMP with a risk based contract in accordance with section 1876 of the Act; 

  

	 	2.	 	Any Medicare Part C health plan that receives a capitated payment from Medicare and which must have its total Medicare beneficiary cost sharing approved by HCFA under section 1854
of the Social Security Act; 

  

	 	3.	 	Medicaid managed care organizations as defined in section 1903(m)(1)(A) that provide or arrange for items or services for Medicaid enrollees under a contract in accordance with
section 1903(m) of the Social Security Act (except for fee-for-service plans or medical savings accounts); 

  

	 	4.	 	Any other health plans that provide or arrange for items and services for Medicaid enrollees in accordance with a risk-based contract with a State agency subject to the upper
payment limits in Sec. 447.361 of Section 42 of the Code of Federal Regulations or an equivalent payment cap approved by the Federal government; 

  

	 	5.	 	Programs For All Inclusive Care For The Elderly (PACE) under sections 1894 and 1934 of the Social Security Act, except for for-profit demonstrations under sections 4801(h) and
4802(h) of Pub. L. 105-33; or 

  

	 	6.	 	A Federally qualified HMO with a risk-based contract under sections 1854 or 1876 of the Social Security Act. Except that a Qualified Participating Plan does not include any
Federally qualified health center receiving supplemental payments 

	 	

	 	1.15.2	 	Bayer reserves the right, with ninety (90) days written notice to Distributor, to disallow any Qualified Participating Plan previously listed on Attachment D.

  

	2.	Allowances 

  

	2.1	Distributor agrees to purchase Bayer Products directly from Bayer in the quantities and at the prices designated in Attachment A. Bayer has no control over the prices for which the
Bayer Test Strips, Controls and Ancillary Products are sold by the Distributor to the End-users. 

  

	 	2.1.1	See Attachment B for Payment terms. 

  

	 	2.1.2	New products introduced by Bayer after the effective date of this Agreement, at Bayer’s discretion, may be included under the terms of this Agreement. 

 

	 	2.1.3	Bayer reserves the right to remove any product offered under the terms of this Agreement. Products so removed will no longer be eligible for allowance pricing under this Agreement.

  

	 	2.1.4	At Bayer’s discretion and upon 30 days notice from Bayer, Bayer may change the Net Price after Allowance for any of the Bayer Products covered by this Agreement.

  

	 	2.1.5	If Distributor fails to meet the Committed Yearly Volume in 50s in the given contract year as set forth on Attachment B, Bayer will invoice Distributor in the amount of shortfall
within 10 days after notification letter is sent. Distributor will remit payment within 30 days of the invoice date. If payment is not received within 30 days of the invoice date all new orders will be held until payment is received.

  

 Page 4 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	2.2	In consideration of the Distributor’s purchases and services set forth herein and the submission of documentation which is acceptable to Bayer, Bayer will provide an allowance
to the Distributor as per pricing levels indicated on Attachment B. 

  

	 	2.2.1	Distributor shall submit documentation as required in Attachment E, in a format acceptable to Bayer, to Bayer HealthCare LLC, Diabetes Care via diabetescaremailorderbayer.com
not later than the fifteenth day of the month following the month that Bayer Test Strips were sold to End-user. 

  

	 	2.2.2	If documentation submitted to Bayer is 90 days or more after Distributor sold Bayer Test Strips to End-user, these will be considered unearned allowances and will be billed back to
Distributor. Payments will be due to Bayer 30 days after notification by Bayer to Distributor. 

  

	2.3	If the documentation submitted by Distributor is insufficient to support the claimed allowances for sales to End-users, or if Bayer’s periodic audits, as detailed in paragraph
1.9, fail to substantiate such information, Bayer will so notify the Distributor who will have ten (10) days from the date of such notification to provide any additional documentation. If Bayer does not receive the documentation within this
period, the allowances issued will be billed back for the unearned allowance and the Distributor shall pay same within thirty (30) days thereof. 

  

	2.4	Bayer will not ship any Bayer Test Strips with less than 6 months dating. 

  

	2.5	The parties intend for this Agreement to comply with the requirements of the Office of Inspector General’s Safe Harbors (“Safe Harbors”), and any safe harbors
available under state law. Therefore the parties agree as follows: 

  

	 	2.5.1	If Distributor sells to an End-user who claims Medicare or Medicaid coverage, Distributor recognizes that any allowances or other price reductions issued by Bayer to Distributor
under this Agreement may constitute a discount under Section 1128B (b) (3) (A) of the Social Security Act [42 USC 1320a-7b (b) (3) (A)]. Accordingly, Distributor agrees, to the extent it may be required, to properly
disclose and appropriately reflect the allowance or reduction in price in any costs claimed or charges made to Medicare, Medicaid, or other federal or state health insurance programs that cover End-users which reimburse the Bayer Meters and/or Bayer
Test Strips and require such disclosure. Distributor shall retain all allowance or other price reduction information and make it available to Medicare, Medicaid or other government agencies in compliance with the discount disclosure requirement.

  

	 	2.5.2	If Distributor sells to an End-user who claims coverage as a member of a Qualified Participating Plan or those End-users who are also covered by Medicare/Medicaid, then Distributor
agrees not to submit claims for reimbursement for Bayer Test Strips to any Federal or State health insurance program, unless permitted by law or regulation. 

  

	 	2.5.3	Where required by law or regulation (e.g., Massachusetts, Minnesota, Missouri, Ohio, Rhode Island and Texas), Distributor will disclose in writing to Participating Plans located in
those States the existence of an agreement between Distributor and Bayer for discounted prices on Bayer Test Strips, and, where appropriate, the availability of free meters, for those Participating Plans’ members. 

  

	 	2.5.4	If any federal or state law or regulation changes or is interpreted in such a way as to call into question whether this Agreement complies with any applicable law or regulations
including Safe Harbors, then Bayer and Distributor will promptly take all necessary steps to bring the requirements of this Agreement into compliance with such applicable laws. 

  

	2.6	Bayer Test Strips are for distribution in the Territory only. 

  

 Page 5 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	2.7	If Bayer is unable to supply *. Dating applies as noted in Paragraph 2.4. 

  

	3.	Bayer Meters 

  

	3.1	As an authorized Distributor of Bayer’s products, as set forth in paragraph 1.2, Distributor can purchase directly from Bayer the *, in accordance with the applicable
Distributor Operating Policy and Procedures of the Bayer Reagent and Instrument Price List, effective at the time of order placement. Bayer has no control over the prices for which the Bayer Meters are sold by the Distributor to End-users.

  

	3.2	During the contract period of this Agreement upon Distributor’s written request, Bayer may provide to Distributor * (“Bayer Meters”) at no cost to Distributor for
distribution directly to End-users and at no cost to End-users. 

  

	 	3.2.1	New products introduced by Bayer after the effective date of this Agreement, at Bayer’s discretion, may be included under the terms of this Agreement. 

 

	 	3.2.2	Bayer reserves the right to remove any Bayer Meter offered under the terms of this Agreement. Bayer Meters so removed shall no longer be subject to this Agreement.

  

	3.3	Bayer, at its sole discretion, reserves the right to limit the number of Bayer Meters provided at no cost to Distributor during the term of this Agreement. 

 

	3.4	Bayer Meters provided at no cost to Distributor by Bayer for distribution directly to End-users, including those distributed through healthcare professional offices at no cost to
End-users may not be billed to Medicare, Medicaid or any other third party insurance held by an End-user and, are not eligible for any Bayer manufacturer’s mail-in rebate/trade-in offer, and each meter will have a sticker indicating the
aforementioned. Distributor may complete warranty card in each End-user’s name and return completed cards to Bayer. 

  

	 	3.4.1	Bayer Meters provided to Distributor by Bayer at no cost for distribution directly to End-users, including those distributed through healthcare professional offices are not for
resale and as such it is the sole responsibility of the Distributor to guarantee that the no cost Bayer Meters provided under this Agreement will be provided only to End-users. 

  

	3.5	In some situations, where Bayer Meters are provided at no cost to Distributor by Bayer for distribution directly to End-users at no cost to End-users, Distributor may request in
writing from Bayer additional sample Bayer Test Strips. Such sample Bayer Test Strips may be required for End-user training and in-service needs and/or to provide End-user a sufficient quantity of Bayer Test Strips in order to adhere to End-user
physician’s recommended level of testing until End-user is able to obtain prescribed quantity from a distributor. 

  

	 	3.5.1	Such sample Bayer Test Strips are provided at no cost to Distributor by Bayer for distribution directly to End-users, including those distributed through healthcare professional
offices, and at no cost to End-users and may not be billed to Medicare, Medicaid or any other third party insurance held by an End-user. Sample Bayer Test Strips provided to Distributor by Bayer at no cost for distribution directly to End-users,
including those distributed through healthcare professional offices are not for resale and as such it is the sole responsibility of the Distributor to guarantee that the no cost sample Bayer Test Strips provided to Distributor will be provided only
to End-users and are not sold. Where required by law or regulation (e.g., Massachusetts, Minnesota, Missouri, Ohio, Rhode Island and Texas), Distributor will disclose, as required, in writing to managed care plans located in those States the
availability of free Sample Bayer Test Strips for those Participating Plans’ members. 

  

 Page 6 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	 	3.5.2	All requests by Distributor for sample Bayer Test Strips should be made in writing to Bayer, and include a description and basis for need for sample Bayer Test Strips.

  

	 	3.5.3	Bayer, at its sole discretion, reserves the right to limit the quantity of sample Bayer Test Strips provided at no cost to Distributor during the term of this Agreement.

  

	3.6	For the term of this Agreement, Distributor agrees to provide only Bayer Test Strips to patients with diabetes for use on a Bayer Meter provided at no cost to Distributor.

  

	 	3.6.1	If the Distributor sells any non Bayer Test Strips to a patient with diabetes for use on a Bayer Meter that was distributed by Bayer at no cost to Distributor, such action shall
constitute grounds for termination of this Agreement immediately upon written notice and removal of Distributor as an Authorized Distributor of Bayer. Bayer has the right to recover all allowances for Bayer Test Strips, Controls and Ancillary
Products as well as the value of all no cost Bayer Meters and Bayer Test Strips provided under this agreement. 

  

	4.	Term 

  

	4.1	This Agreement will commence on the date of acceptance and counter signature by Bayer in accordance with paragraph 8 and shall terminate 36 months from the date of acceptance and
counter signature by Bayer. It may be extended or modified only upon execution on a writing by authorized representatives of both parties. 

  

	4.2	Either party may terminate this Agreement upon thirty (30) days prior written notice. 

  

	4.3	Should Distributor terminate this agreement prior to the end of the (36) month term, or should Bayer terminate this agreement pursuant to sections 4.4, 4.5, or 4.6 prior to the
expiration of the (36) month term, upon termination the Distributor will be charged back as described in 4.3.1, 4.3.2, and/or 4.3.3. 

  

	 	4.3.1	If Distributor elects an early termination or if this contract is terminated by Bayer pursuant to sections 4.4, 4.5, or 4.6 during the first year of the contract, the Distributor
will be charged back the difference between the Net Pricing at the volume level achieved (Refer to Table B) minus the Contracted Net Price, multiplied by the quantity of the Distributor’s actual product purchases for the first year of the
contract unless the total three year volume commitment has been obtained. 

  

	 	4.3.2	If Distributor elects an early termination or if this contract is terminated by Bayer pursuant to sections 4.4, 4.5, or 4.6 during the second year of the contract, the Distributor
will be charged back the difference between the Net Pricing at the year one volume commitment level (Refer to Table B) minus the Contracted Net Price, multiplied by the quantity of the Distributor’s actual product purchases during year one and
year two of the contract unless the total three year volume commitment has been obtained. If Distributor received a chargeback for not reaching the committed volume in year one, only the Distributor’s actual product purchases in year two will
be subject to charge back. 

  

	 	4.3.3	If Distributor elects an early termination or if this contract is terminated by Bayer pursuant to sections 4.4, 4.5, or 4.6 during the third year of the contract, the Distributor
will be charged back the difference between the Net Pricing at the year one volume commitment level (Refer to Table B) minus the Contracted Net Price, multiplied by the quantity of the Distributor’s actual product purchases during year two and
year three of the contract unless the total three year volume commitment has been obtained. If Distributor received a chargeback for not reaching the committed volume in previous years, only the Distributor’s actual product purchases in the
non-charge back years will be subject to charge back. 

  

 Page 7 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	 	4.3.4	Distributor agrees to pay for charge backs described in Sections 4.3.1, 4.3.2, or 4.3.3 within thirty (30) days, upon receipt of an invoice from Bayer HealthCare.

  

	4.4	Bayer may terminate this Agreement immediately upon written notice to the Distributor and recover all allowances received by Distributor under this Agreement and the value of all
free Bayer Meters and free sample Bayer Test Strips provided under this Agreement if Bayer, in its sole judgment, determines that the Distributor has: 

  

	 	4.4.1	Collected or attempted to collect from End-users an amount in excess of the Medicare/Medicaid reimbursement rate and co-payment rate; or 

  

	 	4.4.2	Submitted claims for End-users covered under Qualified Participating Plans or Medicaid Programs that classify Bayer Test Strips as a Pharmacy Benefit; or 

 

	 	4.4.3	Sold the Bayer Test Strips provided to Distributor under this Agreement to parties other than End-users; or 

  

	 	4.4.4	Failed to keep and provide access to Bayer of the documentation set forth in paragraphs 1.5, 1.6, 1.7, and/or 2.2.1.; or 

  

	 	4.4.5	Failed to meet any current or new Medicare/Medicaid regulations or other requirements pertaining to this Agreement or diabetes care services; or 

  

	 	4.4.6	Diverted or sold any Bayer Test Strips intended for Distributor’s End-users and/or Bayer Meters, and/or sample Bayer Test Strips received at no cost from Bayer and intended to
be provided at no cost directly to End-users, to any other Distributor, distribution channel, long term care facility, nursing home, home health agency, physician office, medical clinic, health care professional office, pharmacy, or third party;
except to health care professionals as provided in paragraphs 3.4 and 3.5 or 

  

	 	4.4.7	Displayed or advertised Bayer’s * Test Strips to End-users; or 

  

	 	4.4.8	Failed to provide completed documentation to Bayer on a monthly basis as set forth in paragraphs 1.7 and 2.2.1. 

  

	 	4.4.9	Failed to meet Home Delivery requirement of at least ninety-percent (90%) of Bayer Test Strips covered under this agreement furnished to End User by Mail Mode of Delivery or
Distributor’s Own Delivery Network as described in 1.3. 

  

	4.5	If Distributor violates any terms of this Agreement (including without limitation the failure to make any payment required under this Agreement when such payment becomes due) Bayer
may, in its discretion and without further liability whatsoever, immediately terminate this Agreement. Distributor waives prior notice, service of process and preseizure hearing as prior conditions to repossessions of all Bayer Products still in
Distributor’s possession provided hereunder through this Agreement and shall pay all costs incurred in connection with such repossession (including reasonable attorneys’ fees). If Bayer becomes aware of any breach other than those
identified in paragraph 4.2, Bayer will so notify the Distributor in writing so the Distributor may immediately correct the breach. 

  

	4.6	 If Distributor fails to pay for charge back as described in Attachment B within thirty (30) days upon receipt of an invoice from Bayer, Bayer may immediately
terminate this Agreement. Termination by Bayer pursuant to this provision does not relieve Distributor of it’s obligation to the charge back owed to Bayer and Bayer may pursue all available remedies in law or equity. 

  

 Page 8 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	 	 
Distributor waives prior notice, service of process and preseizure hearing as prior conditions to repossessions of all Bayer Meters and Bayer Test Strips
still in Distributor’s possession provided hereunder through this Agreement and shall pay all costs incurred in connection with such repossession (including reasonable attorneys’ fees). 

  

	5.	Warranty 

  

	5.1	Bayer’s standard warranty terms shall apply to Bayer Products provided under this Agreement. 

  

	6.	General 

  

	6.1	Governing Law: This Agreement will be governed by the laws of the State of New York, without reference to its choice of law provisions. 

  

	6.2	Assignment: This Agreement shall not be assigned by Distributor without the prior written consent of Bayer. 

  

	6.3	Modification: This Agreement contains all the agreements and conditions applicable to this undertaking. All prior oral and written agreements of any kind are superseded. The
terms and conditions of this Agreement shall not be added to, modified, superseded or otherwise altered except by a written modification signed by authorized representatives of both parties except that the products available under this Agreement may
be modified by Bayer, who must give thirty (30) days written notice to Distributor of any changes. The sales representative who represents Bayer HealthCare LLC is not authorized to modify the terms of this Agreement. 

 

	6.4	No Waiver of Conditions: Failure of Bayer to insist on strict performance shall not constitute a waiver of any of the provisions of this Agreement or waiver of any other
default of the Distributor. 

  

	6.5	Trademarks: Bayer retains the exclusive right to its own trademarks, tradenames, servicemarks and symbols, whether existing now or in the future. Distributor may not
advertise or use any tradename, trademark, servicemark or symbol belonging to Bayer without first receiving Bayer’s written consent. 

  

	6.6	Independent Contractor and Indemnification 

  

	 	6.6.1	This Agreement does not create a special or fiduciary relationship between the parties; Distributor is an independent contractor, and nothing in this Agreement is intended to
constitute either party as an agent, legal representative, subsidiary, joint venture, partner, employee, or servant of the other for any purpose whatsoever. 

  

	 	6.6.2	Nothing in this Agreement authorizes Distributor to make any contract, warranty, or representation on Bayer’s behalf or to incur any debt or other obligation in Bayer’s
name. Distributor shall indemnify, defend and hold harmless Bayer, its parent, affiliates, officers, directors, shareholders, employees, successors and assigns from and against any and all claims, demands, losses, costs, expenses (including
reasonable attorneys’ fees and costs), liabilities, judgments and damages arising, directly or indirectly, from, as a result of, or in connection with: (a) the Distributor’s failure to properly perform its obligations under this
Agreement, including a material breach of this Agreement, or (b) a violation of applicable law, rule or regulation by the Distributor and/or its employees or agents. 

  

	 	6.6.3	Nothing in this Agreement authorizes Bayer to make any contract, warranty, or representation on Distributor’s behalf or to incur any debt or other obligation in
Distributor’s name. 

  

 Page 9 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission. 

			
	Certified Diabetic Services	  	 January 23, 2009

  

	6.7	Distributor and Bayer shall maintain confidentiality of all the terms and conditions of the Agreement throughout the duration hereof and for a period of two (2) years following
the effective date of expiration or termination. 

  

	6.8	Distributor represents and warrants that it has not been excluded from participation in the Medicaid, Medicare or other federal or state health insurance programs, nor has the
Distributor been sanctioned in any way by federal or state health care programs. If any such programs initiate action to exclude or sanction the Distributor, written notice shall be sent within ten (10) days of receipt of notice of such action,
as indicated in paragraph 7. 

  

	6.9	The headings contained in this Agreement and in any Exhibit or Schedule hereto are for reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement. 

  

	7.	All notices to the respective parties shall be in writing and shall be mailed to the addresses below. 

  

			
	To Bayer HealthCare LLC:	  	To Distributor:
		
	Bayer HealthCare LLC,	  	Certified Diabetic Services Diabetes Care
	430 South Beiger Street	  	10061 Amberwood Road
	Mishawaka, Indiana 46544	  	Fort Myers, FL 33913
	Attn.: R.W. Anderson	  	Attn.: Fran Ryan,
	Strategic Contracts	  	Chief Operating Officer

  

	7.1	Bayer reserves the right, prior to acceptance of this Agreement by Bayer, to conduct an on-site inspection to verify that Distributor can comply with the terms and requirements of
this Agreement. 

  

	8.	This Agreement will be effective only upon receipt of the requisite information on Attachments B and D, and an example of End-user Information data report format, and counter
signature of Bayer hereon. Distributor should acknowledge their acceptance of this Agreement by signing both copies and returning them to Bayer HealthCare LLC by the close of business February 23, 2009, after which time this proposal
will be considered null and void. If the required information is acceptable to Bayer, Bayer will countersign both copies of the Agreement and return one to Distributor for its records. 

  

									
	 Bayer Healthcare LLC
 Diabetes
Care
	  		  	Certified Diabetic Services
					
	By:	 	 /s/    R.W. Anderson
	  		  	By:	 	 /s/    Francine M. Ryan

		 	Authorized Signature	  		  		 	Authorized Signature
					
		 	 R. W. Anderson
	  		  		 	 Francine M. Ryan

		 	Print Name	  		  		 	Print Name
					
		 	 Manager, Strategic Contracts
	  		  		 	 Chief Operations Officer

		 	Print Title	  		  		 	Print Title
					
		 	 2/13/09
	  		  		 	 2/6/09

		 	Date	  		  		 	Date
					
		 		  		  		 	Franr@cdiabetic.com

  

 Page 10 
  

	*	Redacted materials have been omitted pursuant to a Confidential Treatment Request filed under 17 C.F.R. § 230.406. The omitted materials have been filed separately with the
Office of the Secretary of the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]